최소 단어 이상 선택하여야 합니다.
최대 10 단어까지만 선택 가능합니다.
다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기Journal of Korean Medicine = 대한한의학회지, v.41 no.1, 2020년, pp.107 - 116
정창운 (청연중앙연구소) , 전선우 (청연중앙연구소) , 조희근 (청연중앙연구소)
Objectives: To overcome the limitations of randomized controlled trials, many other trials design is tested. The n-of-1 trial is a promising research method in the field of Korean medicine because of this methodology can examine the optimal treatment for each patient strictly. Therefore, we reviewed...
* AI 자동 식별 결과로 적합하지 않은 문장이 있을 수 있으니, 이용에 유의하시기 바랍니다.
핵심어 | 질문 | 논문에서 추출한 답변 |
---|---|---|
N-of-1 연구가 갖는 의의는 무엇인가? | N-of-1 임상연구는 ‘과학적’ 의학의 확실성을 담보하기 위하여 시도되는 무작위대조시험이 가진 연구 외적타당성의 제한을 극복하고, 실제 임상진료에서 환자 하나하나에 대한 최적의 치료를 시도하기 위한 접근 방식이라고 할 수 있다. 통상적으로 N-of-1 연구는 한 개인에 대해서 ABAB 설계처럼 하나 이상의 가역적 중재와 신뢰할 수 있는 통제를 무작위 순서로, 그리고 효과세척기간(wash-out)을 두어 각 중재에 따른 임상적 경과와의 인과성을 엄격히 평가하게 된다(Fig. | |
증거기반의학(Evidence Based Medicine)은 무엇인가 | 증거기반의학(Evidence Based Medicine)은 의학 연구를 통해 얻어진 다양한 증거들을 임상현장에 접목시키기 위한 주요한 방법론으로 자리매김하고 있다1). 몇몇 한계에도 불구하고 높은 연구 내적타당성을 지니는 무작위대조시험(Randomized Controlled Trial)은 임상의학의 불확실성을 해소시켜줄 수 있어 의학연구의 표준(Gold-Standard)이 되고 있다2-4). | |
무작위대조시험(Randomized Controlled Trial)의 특징은 무엇인가 | 증거기반의학(Evidence Based Medicine)은 의학 연구를 통해 얻어진 다양한 증거들을 임상현장에 접목시키기 위한 주요한 방법론으로 자리매김하고 있다1). 몇몇 한계에도 불구하고 높은 연구 내적타당성을 지니는 무작위대조시험(Randomized Controlled Trial)은 임상의학의 불확실성을 해소시켜줄 수 있어 의학연구의 표준(Gold-Standard)이 되고 있다2-4). 한약과 침구와 같은 한의학적 중재들도 증거기반의학의 철학을 따라 많은 무작위대조시험을 통해 그 효과와 안전성을 입증하고 있다5). |
Akobeng AK. Understanding randomised controlled trials. Archives of Disease in Childhood. 2005; 90: 8. 840-844.
Spieth PM, Kubasch AS, Penzlin AI, Illigens BM, Barlinn K, Siepmann T., Randomized controlled trials - a matter of design., Neuropsychiatric Disease and Treatment. 2016;12. 1341-9.
Suresh K. An overview of randomization techniques: An unbiased assessment of outcome in clinical research. Journal of Human Reproductive Sciences. 2011; 4: 1. 8-11.
Jones DS, Podolsky SH. The history and fate of the gold standard. Lancet. 2015; 385: 9977.1502-3.
Chao J, Dai Y, Verpoorte R, Lam W, Cheng YC, Pao LH, et al. Major achievements of evidence-based traditional Chinese medicine in treating major diseases. Biochemical Pharmacology. 2017; 139. 94-104.
Sackett DL, Rosenberg WM, Gray JA, et al. Evidence based medicine: what it is and what it isn't. BMJ 1996; 312: 7023. 71-2.
Guyatt G, Sackett D, Taylor DW, Chong J, Roberts R, Pugsley S. Determining optimal therapy--randomized trials in individual patients. The New England Journal of Medicine. 1986;314: 14.889-92.
Guyatt GH, Keller JL, Jaeschke R, Rosenbloom D, Adachi JD, Newhouse MT., The n-of-1 randomized controlled trial: clinical usefulness. Our three-year experience. Annals of Internal Medicine. 1990; 112 : 4. 293-9.
Shaffer JA, Kronish IM, Falzon L, Cheung YK, Davidson KW. N-of-1 Randomized Intervention Trials in Health Psychology: A Systematic Review and Methodology Critique. Annals of Behavioral Medicine. 2018; 52: 9. 731-742.
Mirza RD, Punja S, Vohra S, Guyatt G. The history and development of N-of-1 trials. Journal of the Royal Society of Medicine. 2017; 110 : 8. 330-340.
Lillie EO, Patay B, Diamant J, Issell B, Topol EJ, Schork NJ. The n-of-1 clinical trial: the ultimate strategy for individualizing medicine? Personalized Medicine. 2011; 8: 2. 161-173.
Schork NJ. Personalized medicine: Time for one-person trials. Nature. 2015; 520: 7549.609-11.
Terasawa K. Evidence-based Reconstruction of Kampo Medicine: Part-III-How Should Kampo be Evaluated? Evidence-Based Complementary and Alternative Medicine. 2004; 1 :3. 219-222.
Li J, Tian J, Ma B, Yang K. N-of-1 trials in China. Complementary Therapies in Medicine. 2013; 21: 3. 190-4.
Yoshinaga R, Goto Y, Inoue H, Yano H, Nabeshima S, Tahara E. A Case of Lower Back with Extremity Pain Successfully Treated with Kanzobushito. Kampo Medicine. 2019;70: 2. 146-150.
Tsubo T, Unita A, Furuta T, Suzuki M, Ueno T, Suzuki T, et al. A Patient with Diffuse Panbronchiolitis Treated with a Combination of Keishikyoshakuyakukasokyoto and Acupuncture. Kampo Medicine 2019; 70: 2. 99-105.
Yuhong H, Qian L, Yu L, Yingqiang Z, Yanfen L, Shujing Y, et al. An n-of-1 Trial Service in Clinical Practice: Testing the Effectiveness of Liuwei Dihuang Decoction for Kidney-Yin Deficiency Syndrome. Evidence -Based Complementary and Alternative Medicine. 2013; 2013. 827915.
Huang H, Yang P, Xue J, Tang J, Ding L, Ma Y, et al. Evaluating the Individualized Treatment of Traditional Chinese Medicine: A Pilot Study of N-of-1 Trials. Evidence-Based Complementary and Alternative Medicine. 2014; 2014. 148730.
Huang H, Yang P, Wang J, Wu Y, Zi S, Tang J, et al. Investigation into the Individualized Treatment of Traditional Chinese Medicine through a Series of N-of-1 Trials. Evidence-Based Complementary and Alternative Medicine. 2018; 2018. 5813767.
Li J, Niu J, Yang M, Ye P, Zhai J, Yuan W, et al. Using single-patient (n-of-1) trials to determine effectiveness of traditional Chinese medicine on chemotherapy-induced leukopenia in gastric cancer: a feasibility study. Annals of Translational Medicine. 2019; 7: 6. 124.
Li J, Wei D, Niu J, Yang M, Ge L, Wang X, et al. Potential Facilitators and Barriers to Awareness of N-of-1 Trials for Physicians in Traditional Chinese Medicine. Alternative Therapies In Health And Medicine. 2018; 24:2. 44-49.
Xie T, Yu Z. N-of-1 Design and Its Applications to Personalized Treatment Studies. Statistics in Biosciences. 2017; 9: 2. 662-675.
Li J, Hu JY, Zhai JB, Niu JQ, Kwong JSW, Ge L, et al. CONSORT extension for reporting N-of-1 trials for traditional Chinese medicine (CENT for TCM) : Recommendations, explanation and elaboration. Complementary Therapies in Medicine. 2019; 46. 180-188.
Chen J, Huang J, Li JV, Lv Y, He Y, Zheng Q. The Characteristics of TCM Clinical Trials: A Systematic Review of ClinicalTrials.gov. Evidence-Based Complementary and Alternative Medicine. 2017; 2017. 9461415
Kravitz RL, Schmid CH, Marois M, Wilsey B, Ward D, Hays RD, et al. Effect of Mobile Device-Supported Single-Patient Multi-crossover Trials on Treatment of Chronic Musculoskeletal Pain: A Randomized Clinical Trial. JAMA Internal Medicine. 2018; 178: 10. 1368-1377.
Mirza RD, Guyatt GH. A Randomized Clinical Trial of n-of-1 Trials-Tribulations of a Trial. JAMA Internal Medicine. 2018; 178: 10. 1378-1379.
Kravitz RL, Sim I, Duan N. A Case for n-of-1 Trials-Reply. JAMA Internal Medicine. 2019; 179: 3. 453.
Terasawa K. Evidence-based Reconstruction of Kampo Medicine: Part II-The Concept of Sho. Evidence-Based Complementary and Alternative Medicine. 2004; 1: 2. 119-123.
Duan N, Kravitz RL, Schmid CH. Single-patient (n-of-1) trials: a pragmatic clinical decision methodology for patient-centered comparative effectiveness research. Journal of Clinical Epidemiology. 2013; 66: 8 Suppl. S21-8.
Zucker DR, Ruthazer R, Schmid CH. Individual (N-of-1) trials can be combined to give population comparative treatment effect estimates: methodologic considerations. Journal of Clinical Epidemiology 2010; 63: 12. 1312-1323.
Takahashi K, Yoshino T, Maki Y, Ishiuchi K, Namiki T, Ogawa-Ochiai K, et al. Identification of glycyrrhizin metabolites in humans and of a potential biomarker of liquorice-induced pseudoaldosteronism: a multi-centre cross-sectional study. Archives of Toxicology. 2019; 93: 11. 3111-3119.
Sanchez-Vidana DI, Rajwani R, Wong MS. The Use of Omic Technologies Applied to Traditional Chinese Medicine Research. Evidence-Based Complementary and Alternative Medicine. 2017; 2017. 6359730.
*원문 PDF 파일 및 링크정보가 존재하지 않을 경우 KISTI DDS 시스템에서 제공하는 원문복사서비스를 사용할 수 있습니다.
오픈액세스 학술지에 출판된 논문
※ AI-Helper는 부적절한 답변을 할 수 있습니다.